ARTICLE | Product Development
Plus: Neurocrine hits in Phase II depression study and updates from Cerevel, Sage, Ventus, Lilly and AbbVie
By BioCentury Staff
April 24, 2024 1:44 AM UTC
New clinical data for rilzabrutinib and frexalimab from Sanofi (Euronext:SAN; NASDAQ:SNY) advance a pair of new autoimmune disease mechanisms, and the pharma’s strategy for building pipeline-in-a-product assets to treat inflammatory diseases.
The company said it plans to submit regulatory applications in the U.S. and Europe by year-end for covalent, reversible BTK inhibitor rilzabrutinib, after the therapy met the primary endpoint in the Phase III LUNA 3 study to treat chronic immune thrombocytopenia (ITP). Sanofi did not disclose data, so it’s not clear yet how rilzabrutinib will compare with other therapies in development for the indication, such as Vyvgart efgartigimod from Argenx S.E. (Euronext:ARGX; NASDAQ:ARGX)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652204/clinical-report-sanofi-data-advances-pair-of-autoimmune-disease-mechanisms